�DURECT Corporation
(Nasdaq: DRRX) reported that Pain Therapeutics (Nasdaq: PTIE), its
licensee, has submitted an Investigational New Drug (IND) application to
the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid
pain drug candidate based on DURECT's patented ORADUR(TM) technology. This
is the third ORADUR-based opioid drug candidate covered by DURECT's
collaboration with Pain Therapeutics, for which King Pharmaceuticals (NYSE:
KG) holds the commercialization rights. Pain Therapeutics and King
Pharmaceuticals have stated that they expect to denote shortly the
initiation of a clinical study with this new investigational dose
candidate.
"We are very pleased with the advancement and f number with which Pain
Therapeutics and King Pharmaceuticals ar developing this series of four
opioids licensed from us," declared James Brown, Chief Executive Officer of
DURECT. "This marks another milestone for our ORADUR technology as a
versatile platform that provides for the controlled delivery of
pharmaceuticals that are commonly abused."
This new do drugs candidate is the third ORADUR-based opioid drug to enter
developing. The first drug nominee, REMOXY(R) (ORADUR-based oxycodone),
submitted a New Drug Application with the FDA on June 10, 2008 and has been
granted Priority Review Designation by the FDA. Pain Therapeutics has
previously proclaimed positive results from a Phase I clinical trial for a
second of these dose candidates. The active pharmaceutic drug in the
second and third ORADUR-based opioid drug candidate has not been disclosed.
About ORADUR(TM) Technology
ORADUR is a proprietary technology designed to transform short-acting
oral capsule dose forms into sustained liberation oral products, with the
added welfare of being less prone to pervert (e.g. by stifling or weewee
extraction) than other controlled release dose forms on the marketplace today.
Corporate Relationships
In December 2002, DURECT licensed to Pain Therapeutics, Inc. the right
to develop and commercialize on a world-wide basis REMOXY and other oral
sustained release drug candidates exploitation the ORADUR technology which
incorporate quadruplet specified opioid compounds. Under the license agreement,
DURECT is reimbursed for formulation and other work performed under its
agreement with Pain Therapeutics, and will receive extra payments if
certain development and regulatory milestones are achieved with respect to
the commissioned drug candidates. In increase, if commercialised, DURECT will
receive royalties for REMOXY and the other licensed drug candidates of
betwixt 6.0% to 11.5% of net gross revenue of the drug campaigner depending on sales
book as substantially as a mark-up on DURECT's provide of winder excipients used in
the manufacture of the licensed drug candidates. Pain Therapeutics
sublicensed the commercialization rights of REMOXY and other licensed dose
candidates to King Pharmaceuticals in November 2005.
About DURECT Corporation
DURECT is an emerging long suit pharmaceutical company developing
innovational drugs for pain and other inveterate diseases, with late-stage
development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and
TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and
injectable depot delivery technologies enable unexampled indications and superior
clinical/commercial attributes such as abuse deterrence, improved
convenience, compliance, efficacy and safety for small molecule and
biological drugs. For more information, please visit http://www.durect.com.
POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM)
are trademarks of DURECT Corporation. Other referenced trademarks belong to
their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil
are drug candidates under development and have non been sanctioned for
commercialization by the US Food and Drug Administration or other health
authorities.
DURECT Forward Looking Statement
The statements in this press release regarding REMOXY and the second
and third abuse-resistant opioid annoyance medicines under development with King
Pharmaceuticals and Pain Therapeutics, their potential attributes and
market potential, development plans and future clinical trials ar
forward-looking statements involving risks and uncertainties that lav cause
actual results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, just are non limited
to, DURECT's (and that of its one-third party collaborators) abilities to
design, recruit, conduct and complete clinical trials, obtain successful
results from such clinical trials, complete the design, development, and
manufacturing process development of the product campaigner, obtain
regulatory and fabrication approvals from regulatory agencies and
construct and market the ware candidate, as well as marketplace
acceptance of the product nominee. Further info regarding these
and other risks is included in DURECT's Form 10-Q dated August 8, 2008
under the head "Risk Factors."
DURECT Corporation
http://www.durect.com
More info
Tuesday, 2 September 2008
Wednesday, 13 August 2008
Download BoySetsFire
 Artist: BoySetsFire: mp3 download Genre(s): Rock Rock: Punk-Rock Discography:  Unreleased Live Concert Year: 2003 Tracks: 13  Tomorrow Come Today Year: 2003 Tracks: 12  Live For Today Year: 2002 Tracks: 7  After The Eulogy Year: 2001 Tracks: 13  Suckerpunch Training Year: 2000 Tracks: 3  Coalesce Split Year: 2000 Tracks: 2  After the Eulogy Year: 2000 Tracks: 13  Never Give In - At Tribute To The Bad Brains Year: 1999 Tracks: 1  Crush Em All - Boy Sets Fire - Shai Hulud - Split Year: 1999 Tracks: 1  In Chrysalis Year: 1998 Tracks: 5  This Crying, This Screaming, My Voice Is Being Born Year: 1996 Tracks: 6  The Day The Sun Went Out Year: 1996 Tracks: 12  Consider Year: 1995 Tracks: 3 Progressive hard-core band Boy Sets Fire was formed in Delaware in 1994 by isaac M. Singer Nathan Gray, guitarists Josh Latshaw and Chad Istvan, bassist Darrell Hyde, and drummer Matt Krupanski. Self-releasing their debut individual, "Consider," in 1995, Boy Sets Fire shortly resurfaced with a split freeing with Jazz Man's Needle, pickings hail non only for the loudness of their live dates merely likewise the loudness of their political convictions. The band's debut uncut, The Day the Sun Went Out, followed in 1997 and a schism individual with Snapcase preceded the 1999 release of In Chrysalis. Bassist Rob Avery replaced Hyde for 2000's After the Eulogy, the band's number one outlet for novel label Victory Records; This Crying, This Screaming, My Voice Is Being Born was released by and by that summertime. Sucker Punch was issued in early 2001. Male child Sets Fire left Victory for the major label Wind-Up in 2002 and quickly released the Live for Today EP as an introduction. It featured quatern novel tracks and two live recordings. Next, they entered the studio with manufacturer Dave Fortman (12 Rods, Evanescence) to record their full-length Wind-Up debut. Tomorrow Come Today arrived in April 2003 and was a onward motion toward availability. However, the new steering didn't lessen Boy Sets Fire's flaming political convictions in the least. The record album included an incitive political harangue on its inner flap, and its controversial lyrics rankled some religious groups. A modified version of Tomorrow Come Today was also released with an accompanying DVD of live material and under-the-table footage. The band toured behind Tomorrow but, before long later the record's tone ending, lost bassist Avery, whom they replaced with Rob Ehrenbrand. Excite turned out to be a wrong outfit for Boy Sets Fire, so in summertime 2005 they signed with Equal Vision (Burning Heart in Europe), which issued Before the Eulogy that fall. Their whole and eclectic quarter uncut, Misery Index: Notes from the Plague Years, followed in March 2006. Unfortunately, however, the album turned stunned to be their last. By the end of July, the band announced they'd be calling it quits afterward some last shows via a message on their site. Soon later on the annunciation, though, Latshaw had an accident at his construction job and suffered a busted neck, collapsed lung, and two low vertebrae. Boy Sets Fire ruined up their scheduled European tour with their guitar tech pick in, merely waited on circumstance last American dates; their last designate unitedly eventually occurred in early June at Philadelphia's Trocadero Theatre. |
Wednesday, 6 August 2008
Despise
Artist: Despise
Genre(s):
Metal: Death,Black
Discography:
Every Death Give Rise To A Newborn
Year: 2004
Tracks: 6
Marshall Law
Thursday, 26 June 2008
Thursday, 19 June 2008
Girls Aloud's Cheryl Cole To Judge X-Factor
Girls Aloud singer Cheryl Cole has joined the judging panel on the reality TV show X-Factor, it's been announced.
Cole will takeover from Sharon Osbourne, who quit the show last week.
Osbourne revealed earlier this week that the show's producers had approached both Cole and former Spice Girl Mel B to fill the position.
The Girls Aloud singer will join the shows creator Simon Cowell, Louis Walsh and Dannii Minogue on the panel.
In a statement, Cole said it was a “massive honour” to be asked on the show and that production, which begins next week, wouldn't affect her singing career.
"The rest of the girls have said they're right behind me, which is really important for me as it will be weird to be on the other side of the fence this time,” she said.
X-Factor, which last year crowned Leona Lewis as its winner, will be broadcast later this summer.
Is it right that a reality TV show winner should judge a reality TV show? Let us know your thoughts by posting a comment below.
Sign up to see your comment appear automatically.
See Also
Wednesday, 11 June 2008
Wednesday, 4 June 2008
DJ Zany
Artist: DJ Zany
Genre(s):
Other
Discography:
Fusion 08
Year: 2003
Tracks: 2
Fusion 012
Year: 2003
Tracks: 3
Fusion 005
Year: 2002
Tracks: 2
Subscribe to:
Posts (Atom)